A rare case of highly differentiated follicular carcinoma in ovary with FGFR4 Gly388Arg polymorphism: a case report and literature review

被引:3
|
作者
Bao, Yi-Ting [1 ]
Wang, Chao [2 ]
Huang, Wu [1 ]
Yao, Liang-Qing [1 ]
Yuan, Lei [1 ]
机构
[1] Fudan Univ, Dept Gynecol Oncol, Obstet & Gynecol Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Dept Pathol, Obstet & Gynecol Hosp, Shanghai, Peoples R China
关键词
Highly differentiated follicular carcinoma (HDFCO); Malignant struma ovarii; FGFR4; Gly388Arg; Mutation; STRUMA OVARII; PERITONEAL;
D O I
10.1186/s13048-022-01007-y
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Highly differentiated follicular carcinoma (HDFCO) is a rare form of struma-derived thyroid-type carcinoma in ovary, defined as ovarian struma spreading beyond ovary but consisting of benign thyroid tissues. No more than 30 cases of HDFCO have been reported since it was first recognized in 2008. The clinicopathologic and molecular features of HDFCO remain unclear up till now. Case presentation A 38-year-old, para 1 gravida 5 woman has a long history of recurrent right ovarian cysts. Histological evaluation showed the tumor progressed from ovarian mature cystic teratoma (OMCT) to highly differentiated follicular carcinoma (HDFCO) during three relapses. Whole-exome sequencing revealed the germline FGFR4 Gly388Arg polymorphism. Repeated operations were performed to remove lesions for the first two relapses. On the third recurrence, the patient received radical surgery with subsequent thyroidectomy and radioactive iodine ablation. No evidence of disease was observed by February 2022 (8 months). Conclusions The germline FGFR4 Gly388Arg polymorphism may accelerate the malignant transformation of HDFCO, probably by working as a second hit in the developing spectrum.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Fibroblast growth factor receptor 4 (FGFR4) variant p. Gly388Arg in Czech children carcinoma patients
    Valaskova, I.
    Drabova, K.
    Spesna, R.
    Gaillyova, R.
    Sterba, J.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1899 - 1899
  • [22] FGFR4 Gly388Arg polymorphism as predictive markers for a pathological Complete remission with neoadjuvant Chemotherapy for early Breast cancer.
    Dick, M.
    Werft, W.
    Sohn, C.
    Sinn, H. -P.
    Benner, A.
    Burwinkel, B.
    Lichter, P.
    Schneeweiss, A.
    Marme, F.
    ONKOLOGIE, 2010, 33 : 14 - 14
  • [23] FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls
    Bin Xu
    Na Tong
    Shu Q Chen
    Li X Hua
    Zeng J Wang
    Zheng D Zhang
    Ming Chen
    BMC Cancer, 11
  • [24] FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung
    Falvella, Felicia S.
    Frullanti, Elisa
    Galvan, Antonella
    Spinola, Monica
    Noci, Sara
    De Cecco, Loris
    Nosotti, Mario
    Santambrogio, Luigi
    Incarbone, Matteo
    Alloisio, Marco
    Calabro, Elisa
    Pastorino, Ugo
    Skaug, Vidar
    Haugen, Aage
    Taioli, Emanuela
    Dragani, Tommaso A.
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (12) : 2880 - 2885
  • [25] FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls
    Xu, Bin
    Tong, Na
    Chen, Shu Q.
    Hua, Li X.
    Wang, Zeng J.
    Zhang, Zheng D.
    Chen, Ming
    BMC CANCER, 2011, 11
  • [26] FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition
    Ye, Yanwei
    Li, Jie
    Jiang, Dongbao
    Li, Jingjing
    Xiao, Chuangfeng
    Li, Yingze
    Han, Chao
    Zhao, Chunlin
    CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1162 - 1177
  • [27] Association between FGFR4 Gly388Arg polymorphism rs351855 or the IDH1 rs11554137 and Japanese gastric cancer
    Sera, Tomohiro
    Yashiro, Masakazu
    Yamamoto, Yurie
    Kushitani, Yukako
    Sugimoto, Atsushi
    Kushiyama, Syuhei
    Kuroda, Kenji
    Togano, Shingo
    Okuno, Tomohisa
    Yoshii, Mami
    Tamura, Tatsuro
    Toyokawa, Takahiro
    Tanaka, Hiroaki
    Muguruma, Kazuya
    Ohira, Masaichi
    CANCER RESEARCH, 2020, 80 (16)
  • [28] The Gly385(388)Arg Polymorphism of the FGFR4 Receptor Regulates Hepatic Lipogenesis Under Healthy Diet
    Lutz, Stefan Z.
    Hennige, Anita M.
    Peter, Andreas
    Kovarova, Marketa
    Totsikas, Charisis
    Machann, Jurgen
    Kroeber, Stefan M.
    Sperl, Bianca
    Schleicher, Erwin
    Schick, Fritz
    Heni, Martin
    Ullrich, Axel
    Haering, Hans-Ulrich
    Stefan, Norbert
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (06): : 2041 - 2053
  • [29] A gain of function by the cancer-associated FGFR4 c. 1162G>A (p. Gly388Arg) variant
    Ulaganathan, V. K.
    Sperl, B.
    Mayr, T.
    Hornberger, R.
    Rapp, U. R.
    Ullrich, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S107 - S108
  • [30] Association of the fibroblast growth factor receptor-4 (FGFR4) Gly388Arg polymorphism with clinical and pathological response to primary systemic therapy (PST) for early breast cancer (EBC)
    Marme, F.
    Sohn, C.
    Burwinkel, B.
    Sinn, P.
    Hahn, M.
    Lichter, P.
    Benner, A.
    Schneeweiss, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)